Telix Pharmaceuticals Limited ADR (TLX)

$16.78 +0.78 (4.88%)
Market Cap 5.36B
Revenue (ttm) 496.66M
Net Income (ttm) 5.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 81.28
Profit Margin 1.05%
Debt to Equity Ratio 0.00
Volume 31,600
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 334.72M
Stochastic %K 23%
Beta N/A
Analysts Strong Sell
Price Target $25.00

Latest News on TLX

Illuccix® Receives European Approval

Jan 16, 2025, 5:06 PM EST - 1 day ago

Illuccix® Receives European Approval

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 4:35 PM EST - 4 days ago

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Jan 13, 2025, 2:08 AM EST - 5 days ago

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Jan 12, 2025, 5:04 PM EST - 5 days ago

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Dec 30, 2024, 3:45 PM EST - 18 days ago

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Dec 29, 2024, 4:53 PM EST - 19 days ago

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Nov 18, 2024, 6:20 PM EST - 2 months ago

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix ADSs Commence Trading on Nasdaq

Nov 13, 2024, 4:28 PM EST - 2 months ago

Telix ADSs Commence Trading on Nasdaq